Cargando…

Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models

BACKGROUND: Two diagnostic models of prostate cancer (PCa) and clinically significant prostate cancer (CS-PCa) were established using clinical data of among patients whose prostate-specific antigen (PSA) levels are in the gray area (4.0–10.0 ng/ml). MATERIAL/METHODS: Data from 181 patients whose PSA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ming, Ma, Ting, Li, Jun, Zhang, Hai-Jun, Li, Qiang, Wang, Jia-Jia, Sang, Tian, Cao, Chun-Li, Cui, Xin-Wu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879585/ https://www.ncbi.nlm.nih.gov/pubmed/33556045 http://dx.doi.org/10.12659/MSM.929913

Ejemplares similares

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Utility of Free/Total Prostate Specific Antigen (f/t PSA) Ratio in Diagnosis of Prostate Carcinoma
por: Thakur, V., et al.
Publicado: (2004)

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
por: Jung, Jin-Woo, et al.
Publicado: (2019)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA
por: Mašić, Silvija, et al.
Publicado: (2019)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers
por: Li, Qing Kay, et al.
Publicado: (2015)

Usefulness of Total PSA Value in Prostate Diseases Diagnosis
por: Prcic, Alden, et al.
Publicado: (2016)

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
por: Tikkinen, Kari A O, et al.
Publicado: (2018)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml(−1))
por: Liu, Jun, et al.
Publicado: (2019)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Phage display screening identifies a prostate specific antigen (PSA)(–/lo) prostate cancer cell specific peptide to retard castration resistance of prostate cancer
por: Sui, Yi, et al.
Publicado: (2021)

(68)Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone
por: Yang, Jinhui, et al.
Publicado: (2023)

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer
por: Lehrer, S, et al.
Publicado: (2002)

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
por: Ilic, Dragan, et al.
Publicado: (2018)

Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction
por: Ferraro, Simona, et al.
Publicado: (2021)

Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis
por: Huang, Yan, et al.
Publicado: (2018)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone
por: Liu, Junxiao, et al.
Publicado: (2020)

Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements
por: McJimpsey, Erica L.
Publicado: (2016)

Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility
por: Gupta, Nishi, et al.
Publicado: (2017)

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
por: Yin, Ming, et al.
Publicado: (2007)

Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden
por: Rönningås, Ulrika, et al.
Publicado: (2019)

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium
por: Chen, Rui, et al.
Publicado: (2015)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes
por: Llop, Esther, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tjo1vmsa7ip26n3nf4cvbi5k8e